Core Viewpoint - Zhaoke Ophthalmology-B (06622.HK) experienced a significant stock price increase, rising 8.6% to HKD 3.41, marking a new high since October 13 and an overall increase of over 1.8 times in the year [1] Company Developments - Zhaoke Ophthalmology has entered into a distribution and supply agreement with leading Indonesian pharmaceutical company PT Ferron for the commercialization of BRIMOCHOL™PF in Indonesia, an innovative drug licensed from enpoint for the treatment of presbyopia [1] - Under the agreement, Zhaoke Ophthalmology grants PT Ferron exclusive rights to import, promote, distribute, market, and sell the product in Indonesia [1] - The company will receive an upfront payment and may earn additional milestone payments based on specific achievements [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622.HK) has seen a significant increase in its stock price, rising over 7% to 3.38 HKD with a trading volume of 2.3893 million HKD [1] Group 1 - The stock price of Zhaoke Ophthalmology-B increased by 7.64% [1] - The current trading price is reported at 3.38 HKD [1] - The total trading volume reached 238.93 thousand HKD [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant increase in stock price, rising over 7% following the announcement of a distribution and supply agreement with PT Ferron Pharmaceuticals for its innovative drug BRIMOCHOL PF, aimed at treating presbyopia in the Indonesian market [1] Group 1: Company Developments - Zhaoke Ophthalmology has signed a distribution and supply agreement with PT Ferron Pharmaceuticals for BRIMOCHOL PF, granting PT Ferron exclusive rights to import, promote, distribute, market, and sell the product in Indonesia [1] - The agreement includes an upfront payment to Zhaoke Ophthalmology, along with potential milestone payments based on certain achievements [1] Group 2: Product and Regulatory Updates - BRIMOCHOL PF is an innovative drug developed by Tenpoint Therapeutics, which has had its new drug application accepted by the U.S. FDA, with a PDUFA date set for January 28, 2026 [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a stock price increase of over 7% following the announcement of a distribution and supply agreement with PT Ferron Par Pharmaceuticals for its innovative drug BRIMOCHOL™ PF, aimed at treating presbyopia in the Indonesian market [1] Company Developments - Zhaoke Ophthalmology has signed a distribution and supply agreement with PT Ferron, a leading pharmaceutical company in Indonesia, granting exclusive rights for the import, promotion, distribution, marketing, and sale of BRIMOCHOL™ PF in Indonesia [1] - The agreement includes an upfront payment to Zhaoke Ophthalmology, along with potential milestone payments based on certain achievements [1] Product Information - BRIMOCHOL™ PF is an innovative drug developed for the treatment of presbyopia, with its rights licensed from Tenpoint Therapeutics, Ltd. [1] - Tenpoint Therapeutics has submitted a new drug application to the U.S. Food and Drug Administration (FDA), with the Prescription Drug User Fee Act (PDUFA) date set for January 28, 2026 [1]

Company News - BeiGene reported total revenue of approximately $3.845 billion for the first nine months, a year-on-year increase of 43%. Adjusted net profit was approximately $693 million, marking a return to profitability. In Q3, revenue reached $1.412 billion, up 41% year-on-year, with adjusted net profit of approximately $304 million, a 489% increase year-on-year. The growth is primarily attributed to the sales increase of BeiYueZe® in the US and Europe, with the US remaining the largest market for the company. The full-year revenue guidance is set at $5.1 billion to $5.3 billion, reflecting strong growth expectations from BeiYueZe® in the US and continued expansion in Europe and other key global markets [2] - Yidu International Holdings announced an earnings upgrade, expecting a profit attributable to shareholders of approximately HKD 1.2 billion for the first half, representing an increase year-on-year [3] - Hua Hong Semiconductor reported sales revenue of $635 million for Q3 2025, a year-on-year increase of 20.7%. However, net profit decreased by 42.6% to $25.725 million [4] - Autohome's net profit attributable to the parent company for Q3 was approximately RMB 436.6 million, with online marketing and other business revenues increasing by 32.1% year-on-year [5] - Xinyi International reported a cumulative net operating income of approximately HKD 13.981 billion for the first ten months, a year-on-year decrease of about 5.3%, with October revenue at HKD 1.457 billion [6] - Dongfeng Motor Group's cumulative vehicle sales for the first ten months reached 1.501 million units, a year-on-year decline of approximately 1.6%. However, sales of new energy vehicles increased by approximately 37.1% to 421,400 units [7] - China Overseas Land & Investment reported a cumulative contracted property sales amount of approximately RMB 189.165 billion for the first ten months, a year-on-year decrease of 21.3% [8] - Poly Property Group reported a cumulative contracted sales amount of RMB 43.8 billion for the first ten months, a year-on-year decrease of 10.43% [9] - Gemdale reported a cumulative contracted sales amount of approximately RMB 9.125 billion for the first ten months, a year-on-year decrease of 43.93% [10] - Sunac China reported a cumulative contract sales amount of approximately RMB 32.77 billion for the first ten months, a year-on-year decline of 25.1% [11] - Guoyin Financial Leasing plans to purchase 1,198 units of domestic information technology computing equipment for a total consideration of RMB 1.04 billion [12] - Youjia Innovation recently received project designation notifications from a globally renowned automotive group's joint venture and luxury brand, with a total order amount of approximately RMB 320 million [13] - Swire Properties reported a rental rate of 96% for Taikoo Place in Q3, with a rental reduction of 13%. Other Swire properties had an occupancy rate of 90%, with a rental reduction of 15% [14] - Zhongshen Construction Industry plans to acquire 100% equity of Huajian Development Co., Ltd. for approximately HKD 213.6 million [15] - Hard Egg Innovation signed a memorandum of understanding with Huixin Investment to jointly develop an AIoT innovation enterprise incubation platform [16] - Damai Entertainment expects mid-term net profit to increase to no less than RMB 500 million, compared to RMB 337 million last year [17] - Cafe de Coral Group issued a profit warning, expecting mid-term profit attributable to shareholders to decline by 65% to 70% [18] - Qingci Games signed a game licensing transfer agreement with Disney, obtaining authorization to develop and publish the game "Disney: Book of Legends," expected to launch in 2026 across various regions [19] - Now Medical Technology's subsidiary signed a strategic cooperation framework agreement with Medtronic Changzhou to promote clinical applications of real-time navigation tracking endoscopic technology in China [19] - Zhaoke Ophthalmology-B signed a distribution agreement with PT FERRON for the commercialization of BRIMOCHOL PF in Indonesia, receiving an upfront payment and potential milestone payments [19] - Shoujia Technology signed a strategic framework cooperation agreement with Stardust Intelligence, covering the development of humanoid robot tendon and related fields [20] Buyback Dynamics - Helen's decided to exercise its share buyback authorization, planning to repurchase up to 127 million shares [21] - China Feihe repurchased 6.806 million shares for a total of approximately HKD 29.4298 million, with a buyback price of HKD 4.29 to HKD 4.35 [22] - Kintor Pharmaceutical repurchased 1.734 million shares for a total of approximately HKD 26.3078 million, with a buyback price of HKD 14.35 to HKD 15.8 [23] - COSCO Shipping Holdings repurchased 1.53 million shares for a total of approximately HKD 20.9869 million, with a buyback price of HKD 13.57 to HKD 13.84 [24] - Sinopec repurchased 2.398 million H-shares for a total of approximately HKD 10.1066 million, with a buyback price of HKD 4.20 to HKD 4.23 [25]

Group 1 - Company Zhaoke Ophthalmology-B (06622) has entered into a distribution and supply agreement with PT Ferron Par Pharmaceuticals for the commercialization of BRIMOCHOL PF in Indonesia [1] - The agreement grants PT Ferron exclusive rights to import, promote, distribute, market, and sell BRIMOCHOL PF in Indonesia, with the company receiving an upfront payment and potential milestone payments based on specific achievements [1] - BRIMOCHOL PF is an experimental preservative-free eye drop designed to correct near vision loss due to aging, with a new drug application accepted by the FDA, and a review deadline set for January 28, 2026 [1][2] Group 2 - PT Ferron Par Pharmaceuticals, a member of the Dexa Group, has been operating since 2001 and is recognized as one of the top 15 largest pharmaceutical companies in Indonesia [3] - The company has received recognition from regulatory bodies such as the UK's Medicines and Healthcare products Regulatory Agency and Portugal's National Authority of Medicines and Health Products, enhancing its credibility [3] - PT Ferron is known for its diverse product portfolio, advanced production capabilities, and strong strategic partnerships, which contribute to its growing market influence and operational excellence [3]

Group 1 - The company has entered into a distribution and supply agreement with PT Ferron Par Pharmaceuticals for the commercialization of BRIMOCHOL PF in Indonesia, which is an innovative drug licensed by Tenpoint Therapeutics for the treatment of presbyopia [1] - Under the agreement, the company grants PT Ferron exclusive rights to import, promote, distribute, market, and sell BRIMOCHOL PF in Indonesia, and will receive an upfront payment along with potential milestone payments based on specific achievements [1] - The developer of BRIMOCHOL PF, Tenpoint, announced that the FDA has accepted the new drug application for the product, with a review deadline set for January 28, 2026 [1] Group 2 - BRIMOCHOL PF is a preservative-free, experimental eye drop intended for correcting near vision loss due to aging, and is part of a multi-center, randomized, double-blind study involving 629 participants across 47 trial centers in the U.S. [2] - The study compares the safety and efficacy of BRIMOCHOL PF against other formulations, including a single-agent therapy and a carrier eye drop [2] Group 3 - PT Ferron Par Pharmaceuticals, a member of the Dexa Group, has been operating since 2001 and is recognized as one of the top 15 largest pharmaceutical companies in Indonesia according to IQVIA's data [3] - The company has received recognition from regulatory bodies such as the UK's Medicines and Healthcare products Regulatory Agency and Portugal's National Authority of Medicines and Health Products, enhancing its credibility [3] - PT Ferron is strengthening its market influence and operational capabilities through a diversified product portfolio, advanced production capabilities, and strong strategic partnerships [3]

Group 1 - The company has entered into a distribution and supply agreement with PT Ferron Par Pharmaceuticals for the commercialization of BRIMOCHOL™ PF in Indonesia, granting PT Ferron exclusive rights for import, promotion, distribution, marketing, and sales of the product [1] - The company will receive an upfront payment and may earn additional milestone payments based on specific achievements [1] - The developer of BRIMOCHOL™ PF, Tenpoint Therapeutics, announced that the FDA has accepted the new drug application for the product, with a review deadline set for January 28, 2026 [1] Group 2 - BRIMOCHOL™ PF is a preservative-free, experimental eye drop intended to correct near vision loss due to aging, and is part of a multi-center, randomized, double-blind study involving 629 participants across 47 trial centers in the U.S. [2] - The study compares the safety and efficacy of BRIMOCHOL™ PF with other treatments for presbyopia [2] Group 3 - PT Ferron Par Pharmaceuticals, a member of the Dexa Group, has been operating since 2001 and is one of the top 15 largest pharmaceutical companies in Indonesia according to IQVIA data [3] - The company has received recognition from regulatory agencies in the UK and Portugal, enhancing its market influence and operational capabilities through a diverse product portfolio and strong strategic partnerships [3]

Core Viewpoint - The company has entered into a distribution and supply agreement with PT Ferron, a leading pharmaceutical company in Indonesia, for the commercialization of BRIMOCHOL™PF, an innovative drug for treating presbyopia [1] Group 1: Agreement Details - The agreement grants PT Ferron exclusive rights to import, promote, distribute, market, and sell BRIMOCHOL™PF in Indonesia [1] - The company will receive an upfront payment and may earn additional milestone payments based on specific achievements [1] Group 2: Product Information - BRIMOCHOL™PF is a preservative-free, experimental eye drop administered once daily to correct age-related near vision loss [1] - The drug developer, Tenpoint, announced that the FDA has accepted the new drug application for BRIMOCHOL™PF, with a review deadline set for January 28, 2026 [1] Group 3: Clinical Study - BRIO-II is a three-arm, multi-center, randomized, double-blind study assessing the safety and efficacy of BRIMOCHOL™PF compared to other treatments, involving 629 participants across 47 trial centers in the U.S. [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Zhaoke Ophthalmology Limited 關於老花眼 （於英屬處女群島註冊成立並於開曼群島存續的有限公司） 兆科眼科有限公司 （股份代號：6622） 自 願 性 公 佈－就 於 印 度 尼 西 亞 商 業 化BRIMOCHOL™ PF 與PT FERRON訂立分銷協議 本 公 告 乃 由 兆 科 眼 科 有 限 公 司（「本公司」）董 事 會（「董事會」）自 願 作 出。 本 公 司 董 事 會 欣 然 宣 佈，本 公 司 與 領 先 印 度 尼 西 亞 製 藥 公 司PT Ferron Par Pharmaceuticals（「PT Ferron」）就 於 印 度 尼 西 亞 商 業 化BRIMOCHOL™ PF（由Tenpoint Therapeutics, Ltd.（「Tenpoint」）授 出 許 可 權 的 創 新 藥，用 ...